40
Participants
Start Date
April 19, 2015
Primary Completion Date
August 25, 2021
Study Completion Date
August 25, 2021
Erlotinib
Participants received erlotinib 150 mg for the 21-day cycle.
Bemcentinib
Participants received bemcentinib 600 mg on Days 1 and 2 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
Bemcentinib
"Participants received starting loading dose of bemcentinib 600 mg (200 mg on Days 1, 2 and 3) and bemcentinib 100 mg as daily maintenance dose for the 21-day cycle.~Depending on tolerability and DLT, the loading dose of bemcentinib was escalated to 800mg (400 mg on Days 1 and 2) and bemcentinib 100 mg as daily maintenance for the 21- day cycle and to 1200 mg daily (600 mg on Days 1 and 2, or 400 mg on Days 1, 2 and 3) and bemcentinib 200 mg as daily maintenance for the 21- day cycle)."
Bemcentinib
Participants received bemcentinib 400 mg on Days 1, 2 and 3 as loading dose and bemcentinib 200 mg as daily maintenance dose for the 21-day cycle.
Moffitt Cancer Center, Tampa
The Sarah Cannon Research Institute Tennessee Oncology PLLC, Nashville
Horizon Oncology Research,, Lafayette
Henry Ford Health System, Detroit
Mary Crowley Cancer Research Centers, Dallas
MD Anderson Cancer Center, Houston
Oncology Consultants PA, Houston
USC/Norris Comprehensive Cancer Center, Los Angeles
UC San Diego Moores Cancer Center, La Jolla
Southwestern Medical Center, Dallas
Lead Sponsor
BerGenBio ASA
INDUSTRY